AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24748637 — intervention group
Group type: COMPARATOR
Intervention: Ca
Number of subjects: 72
Study 22699926 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured wellness program (8 sessions of stress management)
Number of subjects: 449
Study 22699926 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 449
Study 18212316 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding with conventional diabetes care
Number of subjects: 60
Study 18212316 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes therapy with a focus on weight loss by lifestyle change
Number of subjects: 60
Study 16180593 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm therapy programme (15‐20 45‐min sessions) based on repetition of unilateral and symmetrical bilateral tasks
Number of subjects: 41
Study 16180593 — intervention group
Group type: COMPARATOR
Intervention: Usual arm therapy of a similar duration and frequency to the experimental treatment
Number of subjects: 41
Study 12966125 — intervention group
Group type: EXPERIMENTAL
Intervention: Shiga toxin-binding agent (500 mg/kg daily for 7 days)
Number of subjects: 145
Study 12966125 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cornmeal)
Number of subjects: 145
Study 11005561 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PAI‐1 levels
Number of subjects: 594
Study 11005561 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CRP levels
Number of subjects: 594
Study 11005561 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CRP
Number of subjects: 594
Study 11005561 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CRP (excluding Dukes' D disease)
Number of subjects: 594
Study 9001924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepoxalin 25 mg
Number of subjects: 0
Study 9001924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepoxalin 100 mg
Number of subjects: 0
Study 9001924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepoxalin 200 mg
Number of subjects: 0
Study 9001924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepoxalin 400 mg
Number of subjects: 0
Study 9001924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepoxalin 800 mg
Number of subjects: 0
Study 9001924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepoxalin 400 mg (multiple dose)
Number of subjects: 0
Study 9001924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1623755 — intervention group
Group type: EXPERIMENTAL
Intervention: Supranormal hemodynamic and oxygen transport values
Number of subjects: 253
Study 1623755 — intervention group
Group type: COMPARATOR
Intervention: Normal hemodynamic values
Number of subjects: 253
Study 3883168 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy
Number of subjects: 1665
Study 3883168 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastectomy without axillary dissection but with regional irradiation
Number of subjects: 1665
Study 3883168 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastectomy without irradiation plus axillary dissection if nodes were positive
Number of subjects: 1665
Study 30869642 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care with therapist-assisted I-CBT followed by f2f CBT if needed
Number of subjects: 363
Study 30869642 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) - face-to-face CBT
Number of subjects: 363
Study 30202185 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning (CEP)
Number of subjects: 1018
Study 30202185 — intervention group
Group type: COMPARATOR
Intervention: Resources for Services (RS)
Number of subjects: 1018
Study 27347792 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual reminiscence sessions (5 weekly sessions)
Number of subjects: 41
Study 25391143 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent video game—offline
Number of subjects: 101
Study 25391143 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent video game—online
Number of subjects: 101
Study 25391143 — intervention group
Group type: COMPARATOR
Intervention: Neutral video game—offline
Number of subjects: 101
Study 25391143 — intervention group
Group type: COMPARATOR
Intervention: Neutral video game—online
Number of subjects: 101
Study 22409644 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 10 weeks, supplemented with up to 4 caregiver educational sessions.
Number of subjects: 80
Study 20207977 — intervention group
Group type: EXPERIMENTAL
Intervention: Two stents and cataract surgery (group 1)
Number of subjects: 33
Study 20207977 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery alone (group 2)
Number of subjects: 33
Study 19996048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 715
Study 15956632 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg, 3 times daily for 1 year)
Number of subjects: 539
Study 15956632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times daily for 1 year)
Number of subjects: 539
Study 12591751 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress (high skin and core temperatures)
Number of subjects: 8
Study 12591751 — intervention group
Group type: COMPARATOR
Intervention: Normal conditions (normal skin and core temperatures)
Number of subjects: 8
Study 10579613 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate (3.6 mg depot once every 28 days for four months, followed by additional cycles if menorrhagia occurred)
Number of subjects: 72
Study 10579613 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 72
Study 8729530 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 24
Study 1931534 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioavail slow-release theophylline capsule
Number of subjects: 10
Study 1931534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7091036 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy supplementation of 1000 kcal/day (group II)
Number of subjects: 224
Study 7091036 — intervention group
Group type: COMPARATOR
Intervention: Energy supplementation of 200 kcal/day (group I)
Number of subjects: 224
Study 30238736 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum Sealing Drainage (VSD)
Number of subjects: 80
Study 30238736 — intervention group
Group type: COMPARATOR
Intervention: External dressing (Control)
Number of subjects: 80
Study 26460697 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting parenting support program
Number of subjects: 428
Study 26460697 — intervention group
Group type: EXPERIMENTAL
Intervention: Father support satisfaction
Number of subjects: 428
Study 24289920 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (600 mg weekly for 4 weeks followed by 900 mg every 2 weeks until week 24; or 900 mg weekly for 4 weeks followed by 1200 mg every 2 weeks until week 24)
Number of subjects: 30
Study 24289920 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 30
Study 24289920 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 30
Study 24289920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22344966 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified doogh (FD; 500 IU/250 mL, n=50)
Number of subjects: 100
Study 22344966 — intervention group
Group type: COMPARATOR
Intervention: Plain doogh (PD; no detectable vitamin D/250 mL, n=50)
Number of subjects: 100
Study 19568826 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.4 mg/kg mean final dose)
Number of subjects: 105
Study 19568826 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 105
Study 19568826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 17646192 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with ischaemic ECG changes
Number of subjects: 3143
Study 17646192 — intervention group
Group type: COMPARATOR
Intervention: Men with ischaemic ECG changes
Number of subjects: 3143
Study 17646192 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with major ECG changes
Number of subjects: 3143
Study 17646192 — intervention group
Group type: COMPARATOR
Intervention: Men with major ECG changes
Number of subjects: 3143
Study 17646192 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite CAD in women
Number of subjects: 3143
Study 17646192 — intervention group
Group type: COMPARATOR
Intervention: Definite CAD in men
Number of subjects: 3143
Study 15970067 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1-8 mg)
Number of subjects: 160
Study 15970067 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide (2.5 mg)
Number of subjects: 160
Study 12584534 — intervention group
Group type: COMPARATOR
Intervention: PICC insertion
Number of subjects: 1650
Study 12584534 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of PICC placement and line complications (blockage or leaking)
Number of subjects: 1650
Study 12584534 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval of embolized line fragment
Number of subjects: 1650
Study 11130295 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle influences
Number of subjects: 0
Study 11130295 — intervention group
Group type: EXPERIMENTAL
Intervention: Social deprivation
Number of subjects: 0
Study 8880057 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 50 mg 3 times daily for 7 or 8 days
Number of subjects: 8
Study 8880057 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat with furosemide
Number of subjects: 8
Study 8880057 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat with nifedipine
Number of subjects: 8
Study 8880057 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat with captopril
Number of subjects: 8
Study 8880057 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat with atenolol
Number of subjects: 8
Study 1710919 — intervention group
Group type: EXPERIMENTAL
Intervention: COP-BLAM/IMVP-16 protocol
Number of subjects: 548
Study 1710919 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiotherapy
Number of subjects: 548
Study 6150771 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus saline
Number of subjects: 6
Study 6150771 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus cimetidine
Number of subjects: 6
Study 6150771 — intervention group
Group type: COMPARATOR
Intervention: Insulin plus dextrose
Number of subjects: 6
Study 30219887 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 640
Study 30219887 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 640
Study 31803504 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR inhibitors (cetuximab or panitumumab) plus oxaliplatin or irinotecan-based chemotherapy
Number of subjects: 261
Study 28806430 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional technique (6 clinical sessions)
Number of subjects: 20
Study 28806430 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated technique (3 clinical sessions)
Number of subjects: 20
Study 28806430 — intervention group
Group type: COMPARATOR
Intervention: Baseline with old dentures
Number of subjects: 20
Study 26159137 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence Care Protocol
Number of subjects: 120
Study 26159137 — intervention group
Group type: COMPARATOR
Intervention: Conventional skin care
Number of subjects: 120
Study 24195949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal SP‐SAP (20‐60 ?g) in addition to standard‐of‐care analgesic therapy
Number of subjects: 70
Study 24195949 — intervention group
Group type: COMPARATOR
Intervention: Standard‐of‐care analgesic therapy alone (control)
Number of subjects: 70
Study 21626017 — intervention group
Group type: EXPERIMENTAL
Intervention: LED therapy (GaAlAs, 640 nm, 4 J/cm(2), 0.10 W, 70 s)
Number of subjects: 55
Study 21626017 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (InGaAlP, 660 nm, 4 J/cm(2), 0.03 W, 25 s)
Number of subjects: 55
Study 21626017 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 18633599 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol 5 mg/ml (group A)
Number of subjects: 52
Study 18633599 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol 10 mg/ml (group B)
Number of subjects: 52
Study 18633599 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol 10 mg/ml (additional treatment for unsatisfied patients)
Number of subjects: 52
Study 16418023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg intravenously
Number of subjects: 75
Study 16418023 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.4 mg/kg intravenously
Number of subjects: 75
Study 16418023 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 75
Study 14508404 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation
Number of subjects: 6
Study 14508404 — intervention group
Group type: COMPARATOR
Intervention: Tracheal suctioning
Number of subjects: 6
Study 10828671 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine (15 mg t.i.d.)
Number of subjects: 98
Study 10828671 — intervention group
Group type: COMPARATOR
Intervention: Placebo (t.i.d.)
Number of subjects: 98
Study 9126713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-existential group therapy integrated over 6 months with adjuvant chemotherapy.
Number of subjects: 0
Study 9126713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-existential group therapy
Number of subjects: 0
Study 8095119 — intervention group
Group type: EXPERIMENTAL
Intervention: mezlocillin intravenously
Number of subjects: 0
Study 8095119 — intervention group
Group type: COMPARATOR
Intervention: not treated with mezlocillin (control)
Number of subjects: 0
Study 2876741 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion (250 micrograms/h continuously during 120 h)
Number of subjects: 60
Study 2876741 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (200 mg IV every 4 h for 5 days) and pirenzepine (10 mg IV every 8 h for 5 days)
Number of subjects: 60
Study 31602530 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet transplantation (IT)
Number of subjects: 29
Study 31602530 — intervention group
Group type: EXPERIMENTAL
Intervention: Thresholds for diagnosing IT success at 6 months post-transplant: SD at 22.76 mg/dL (sensitivity 88.89%, specificity 80.00%); CV at 17.47% (sensitivity 88.89%, specificity 70.00%); MAGE at 54.81 mg/dL (sensitivity 88.89%, specificity 80.00%); GVP at 12.27% (sensitivity 88.89%, specificity 70.00%).
Number of subjects: 29
Study 29422651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-hormone closed-loop system (DH-CLS) with simplified meal bolus approach for 75g carbohydrate meal
Number of subjects: 20
Study 29422651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-hormone closed-loop system (DH-CLS) with simplified meal bolus approach for 45g carbohydrate meal
Number of subjects: 20
Study 29422651 — intervention group
Group type: EXPERIMENTAL
Intervention: Overestimated meal insulin bolus for 75g carbohydrate meal
Number of subjects: 20
Study 29422651 — intervention group
Group type: EXPERIMENTAL
Intervention: Overestimated meal insulin bolus for 45g carbohydrate meal
Number of subjects: 20
Study 29422651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-hormone closed-loop system (DH-CLS) with simplified meal bolus approach
Number of subjects: 20
Study 26210058 — intervention group
Group type: EXPERIMENTAL
Intervention: Active DLPFC stimulation (bipolar-balanced montage)
Number of subjects: 60
Study 26210058 — intervention group
Group type: COMPARATOR
Intervention: Sham DLPFC stimulation
Number of subjects: 60
Study 26210058 — intervention group
Group type: EXPERIMENTAL
Intervention: Active DLPFC stimulation (bipolar-unbalanced montage)
Number of subjects: 60
Study 24898426 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated femoral strength from finite element analysis of DXA scans
Number of subjects: 7860
Study 24898426 — intervention group
Group type: COMPARATOR
Intervention: Total hip BMD
Number of subjects: 7860
Study 24898426 — intervention group
Group type: COMPARATOR
Intervention: Femoral neck (FN) BMD
Number of subjects: 7860
Study 24898426 — intervention group
Group type: COMPARATOR
Intervention: FRAX scores
Number of subjects: 7860
Study 24898426 — intervention group
Group type: COMPARATOR
Intervention: Hip structure analysis (HSA) variables
Number of subjects: 7860
Study 24898426 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated femoral strength
Number of subjects: 7860
Study 22903395 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus zoledronic acid
Number of subjects: 294
Study 22903395 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 294
Study 20406425 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal report of any signs of neonatal illness
Number of subjects: 16059
Study 20406425 — intervention group
Group type: COMPARATOR
Intervention: Community health workers (CHWs) assessment of neonatal illness
Number of subjects: 16059
Study 18690349 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) administration for four consecutive days after thermal injury
Number of subjects: 31
Study 18690349 — intervention group
Group type: COMPARATOR
Intervention: Non-antithrombin (non-AT) treatment
Number of subjects: 31
Study 15978306 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg plus HCTZ 12.5 mg OD
Number of subjects: 1079
Study 15978306 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg plus HCTZ 25 mg OD
Number of subjects: 1079
Study 15978306 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg OD
Number of subjects: 1079
Study 12633189 — intervention group
Group type: COMPARATOR
Intervention: Soap and water
Number of subjects: 0
Study 12633189 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate
Number of subjects: 0
Study 12633189 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine-containing towels
Number of subjects: 0
Study 12633189 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterless rub containing 61% ethyl alcohol
Number of subjects: 0
Study 10500023 — intervention group
Group type: EXPERIMENTAL
Intervention: Black currant seed oil (BCSO) supplementation for 2 months
Number of subjects: 40
Study 10500023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soybean oil)
Number of subjects: 40
Study 8992964 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg paracetamol suppository
Number of subjects: 18
Study 8992964 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg paracetamol suppository
Number of subjects: 18
Study 8992964 — intervention group
Group type: COMPARATOR
Intervention: 500 mg cut-in-half paracetamol tablet
Number of subjects: 18
Study 1881721 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum visit with primary care provider and telephone access
Number of subjects: 251
Study 1881721 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postpartum visit)
Number of subjects: 251
Study 6104935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg orally at 2200 h and 0800 h
Number of subjects: 50
Study 6104935 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg orally at the same times
Number of subjects: 50
Study 6104935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg orally
Number of subjects: 50
Study 6104935 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg orally
Number of subjects: 50
Study 6104935 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 50
Study 30695075 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront point-of-care testing
Number of subjects: 0
Study 28777756 — intervention group
Group type: EXPERIMENTAL
Intervention: Safinamide
Number of subjects: 0
Study 28777756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26414562 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass surgery with minimal gastric resection (DJBm)
Number of subjects: 17
Study 26414562 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 17
Study 23419665 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical masking ODT
Number of subjects: 0
Study 23419665 — intervention group
Group type: EXPERIMENTAL
Intervention: Gustatory masking ODT
Number of subjects: 0
Study 17940025 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of integrative body‐mind training (20 minutes per day)
Number of subjects: 40
Study 17940025 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 40
Study 15497662 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Kolestor)
Number of subjects: 24
Study 15497662 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 24
Study 10886610 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bread diet
Number of subjects: 0
Study 10886610 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bread diet
Number of subjects: 0
Study 10886610 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 9481974 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam intravenously
Number of subjects: 24
Study 9481974 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam rectally
Number of subjects: 24
Study 9481974 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg diazepam rectally
Number of subjects: 24
Study 7913572 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromperidol
Number of subjects: 45
Study 7913572 — intervention group
Group type: COMPARATOR
Intervention: Sulpiride
Number of subjects: 45
Study 7913572 — intervention group
Group type: COMPARATOR
Intervention: Bromperidol and Sulpiride
Number of subjects: 45
Study 3525029 — intervention group
Group type: EXPERIMENTAL
Intervention: TCDO (Oxoferin)
Number of subjects: 60
Study 3525029 — intervention group
Group type: COMPARATOR
Intervention: Beta-isodona
Number of subjects: 60
Study 30171452 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-tailored counseling center for PrEP
Number of subjects: 50
Study 30171452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 50
Study 30184543 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly cetuximab (500 mg/m2)
Number of subjects: 36